Impulsive behavior and nicotinic acetylcholine receptors

Journal of Pharmacological Sciences

Volumn 118, Issue 4, 2012, Pages 413-422

  Ohmura, Yu ^a   Tsutsui Kimura, Iku ^a   Yoshioka, Mitsuhiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Attention deficit hyperactivity disorder (ADHD); Impulsive action; Inhibitory control; Nicotine; Nucleus accumbens

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; ATOMOXETINE; CLOZAPINE; DOPAMINE; ISPRONICLINE; MILNACIPRAN; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; RIMONABANT;

ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BRAIN FUNCTION; CONTINUOUS INFUSION; DEPRESSION; DISEASE MODEL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMPULSIVENESS; INHIBITION (PSYCHOLOGY); NERVE STIMULATION; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PREFRONTAL CORTEX; PROTEIN DEPLETION; PROTEIN FUNCTION; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

EID: 84867194399     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11R06CR     Document Type: Review

References (100)

1. Daruna JH, Barnes PA. A neurodevelopmental view of impulsivity. In: McCown WG JJ, Shure MB, editors. The impulsive client: theory research and treatment. Washington, DC: American Psychological Association; 1993. p. 22-37.
2. Ohmura Y, Takahashi T, Kitamura N, Wehr P. Three-month stability of delay and probability discounting measures. Exp Clin Psychopharmacol. 2006;14:318-328.
3. Fawcett TW, McNamara JM, Houston AI. When is it adaptive to be patient? A general framework for evaluating delayed rewards. Behav Processes. 2012;89:128-136.
4. Johnson DD, Fowler JH. The evolution of overconfidence. Nature. 2011;477:317-320.
5. Babinski LM, Hartsough CS, Lambert NM. Childhood conduct problems, hyperactivity-impulsivity, and inattention as predictors of adult criminal activity. J Child Psychol Psychiatry. 1999;40:347-355.
6. Perry JL, Larson EB, German JP, Madden GJ, Carroll ME. Impulsivity (delay discounting) as a predictor of acquisition of IV cocaine self-administration in female rats. Psychopharmacology (Berl). 2005;178:193-201.
7. Swann AC, Dougherty DM, Pazzaglia PJ, Pham M, Steinberg JL, Moeller FG. Increased impulsivity associated with severity of suicide attempt history in patients with bipolar disorder. Am J Psychiatry. 2005;162:1680-1687.
8. Diergaarde L, Pattij T, Poortvliet I, Hogenboom F, de Vries W, Schoffelmeer AN, et al. Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats. Biol Psychiatry. 2008;63:301-308.
9. Losier BJ, McGrath PJ, Klein RM. Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: a meta-analytic review. J Child Psychol Psychiatry. 1996;37:971-987.
10. Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. 2008;33:480-490.
11. Swann AC, Dougherty DM, Pazzaglia PJ, Pham M, Moeller FG. Impulsivity: a link between bipolar disorder and substance abuse. Bipolar Disord. 2004;6:204-212.
12. Strakowski SM, Fleck DE, DelBello MP, Adler CM, Shear PK, McElroy SL, et al. Characterizing impulsivity in mania. Bipolar Disord. 2009;11:41-51.
13. Dom G, De Wilde B, Hulstijn W, van den Brink W, Sabbe B. Behavioural aspects of impulsivity in alcoholics with and without a cluster-B personality disorder. Alcohol Alcohol. 2006;41:412-420.
14. Mitchell SH. Measures of impulsivity in cigarette smokers and non-smokers. Psychopharmacology (Berl). 1999;146:455-464.
15. Dalley JW, Everitt BJ, Robbins TW. Impulsivity, compulsivity, and top-down cognitive control. Neuron. 2011;69:680-694.
16. Clark L, Robbins TW, Ersche KD, Sahakian BJ. Reflection impulsivity in current and former substance users. Biol Psychiatry. 2006;60:515-522.
17. Winstanley CA. The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders. Br J Pharmacol. 2011;164:1301-1321.
18. Reynolds B, de Wit H, Richards J. Delay of gratification and delay discounting in rats. Behav Processes. 2002;59:157.
19. Ohmura Y, Takahashi T, Kitamura N. Discounting delayed and probabilistic monetary gains and losses by smokers of cigarettes. Psychopharmacology (Berl). 2005;182:508-515.
20. Ohmura Y, Jutkiewicz EM, Domino EF. L-DOPA attenuates nicotine withdrawal-induced behaviors in rats. Pharmacol Biochem Behav. 2011;98:552-558.
21. Ohmura Y, Jutkiewicz EM, Yoshioka M, Domino EF. 5-Hydroxytryptophan attenuates somatic signs of nicotine withdrawal. J Pharmacol Sci. 2011;117:121-124.
22. Bickel WK, Odum AL, Madden GJ. Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. Psychopharmacology (Berl). 1999;146:447-454.
23. Heyman GM, Gibb SP. Delay discounting in college cigarette chippers. Behav Pharmacol. 2006;17:669-679.
24. Reynolds B. Do high rates of cigarette consumption increase delay discounting? A cross-sectional comparison of adolescent smokers and young-adult smokers and nonsmokers. Behav Processes. 2004;67:545-549.
25. Blondel A, Sanger DJ, Moser PC. Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies. Psychopharmacology (Berl). 2000;149: 293-305.
26. Dallery J, Locey ML. Effects of acute and chronic nicotine on impulsive choice in rats. Behav Pharmacol. 2005;16:15-23.
27. Tsutsui-Kimura I, Ohmura Y, Izumi T, Yamaguchi T, Yoshida T, Yoshioka M. The effects of serotonin and/or noradrenaline reuptake inhibitors on impulsive-like action assessed by the three-choice serial reaction time task: a simple and valid model of impulsive action using rats. Behav Pharmacol. 2009;20: 474-483.
28. Tsutsui-Kimura I, Ohmura Y, Izumi T, Yamaguchi T, Yoshida T, Yoshioka M. Nicotine provokes impulsive-like action by stimulating alpha4beta2 nicotinic acetylcholine receptors in the infralimbic, but not in the prelimbic cortex. Psychopharmacology (Berl). 2010;209:351-359.
29. Cordero-Erausquin M, Marubio LM, Klink R, Changeux JP. Nicotinic receptor function: new perspectives from knockout mice. Trends Pharmacol Sci. 2000;21:211-217.
30. Grottick AJ, Higgins GA. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res. 2000;117:197-208.
31. Hoyle E, Genn RF, Fernandes C, Stolerman IP. Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl). 2006;189:211-223.
32. Tsutsui-Kimura I, Ohmura Y, Izumi T, Yamaguchi T, Yoshida T, Yoshioka M. Endogenous acetylcholine modulates impulsive action via alpha4beta2 nicotinic acetylcholine receptors in rats. Eur J Pharmacol. 2010;641:148-153.
33. Nisell M, Nomikos GG, Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse. 1994;16:36-44.
34. Cadoni C, Di Chiara G. Differential changes in accumbens shell and core dopamine in behavioral sensitization to nicotine. Eur J Pharmacol. 2000;387:R23-R25.
35. Liang Y, Boules M, Shaw AM, Williams K, Fredrickson P, Richelson E. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Brain Res. 2008;1231:6-15.
36. Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, et al. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci. 2003;17:1329-1337.
37. Reperant C, Pons S, Dufour E, Rollema H, Gardier AM, Maskos U. Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knockout mice with selective re-expression of the beta2 subunit in the ventral tegmental area. Neuropharmacology. 2010;58:346-350.
38. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P, et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry. 2004;161:1211-1218.
39. Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z, Scheibal D, Abrams AL, et al. Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology. 2009;34:282-289.
40. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM. The effect of nicotine on striatal dopamine release in man: a [11C]raclopride PET study. Synapse. 2007;61:637-645.
41. Cole BJ, Robbins TW. Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi on performance of a 5-choice serial reaction time task in rats: implications for theories of selective attention and arousal. Behav Brain Res. 1989;33:165-179.
42. Pattij T, Janssen MC, Vanderschuren LJ, Schoffelmeer AN, van Gaalen MM. Involvement of dopamine D1 and D2 receptors in the nucleus accumbens core and shell in inhibitory response control. Psychopharmacology (Berl). 2007;191:587-598.
43. Buhusi CV, Meck WH. What makes us tick? Functional and neural mechanisms of interval timing. Nat Rev Neurosci. 2005;6:755-765.
44. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl). 2007;191:391-431.
45. Sokolowski JD, Salamone JD. Effects of dopamine depletions in the medial prefrontal cortex on DRL performance and motor activity in the rat. Brain Res. 1994;642:20-28.
46. Loos M, Pattij T, Janssen MC, Counotte DS, Schoffelmeer AN, Smit AB, et al. Dopamine receptor D1/D5 gene expression in the medial prefrontal cortex predicts impulsive choice in rats. Cereb Cortex. 2010;20:1064-1070.
47. Kitaichi Y, Inoue T, Izumi T, Nakagawa S, Tanaka T, Masui T, et al. Effect of co-administration of a serotonin-noradrenaline reuptake inhibitor and a dopamine agonist on extracellular monoamine concentrations in rats. Eur J Pharmacol. 2008;584:285-290.
48. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711.
49. Robinson ES, Eagle DM, Mar AC, Bari A, Banerjee G, Jiang X, et al. Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology. 2008;33:1028-1037.
50. Li Z, Prus AJ, Dai J, Meltzer HY. Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. J Pharmacol Exp Ther. 2009;330:948-955.
51. Amitai N, Semenova S, Markou A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl). 2007;193:521-537.
52. Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat. J Neurochem. 2000;75:1147-1154.
53. Greco B, Invernizzi RW, Carli M. Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268. Psychopharmacology (Berl). 2005;179:68-76.
54. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol. 2003;138:544-553.
55. Schmidt CJ, Fadayel GM. The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol. 1995;273:273-279.
56. Winstanley CA, Chudasama Y, Dalley JW, Theobald DE, Glennon JC, Robbins TW. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berl). 2003;167:304-314.
57. Couey JJ, Meredith RM, Spijker S, Poorthuis RB, Smit AB, Brussaard AB, et al. Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron. 2007;54:73-87.
58. Passetti F, Chudasama Y, Robbins TW. The frontal cortex of the rat and visual attentional performance: dissociable functions of distinct medial prefrontal subregions. Cereb Cortex. 2002;12:1254-1268.
59. Chudasama Y, Passetti F, Rhodes SE, Lopian D, Desai A, Robbins TW. Dissociable aspects of performance on the 5-choice serial reaction time task following lesions of the dorsal anterior cingulate, infralimbic and orbitofrontal cortex in the rat: differential effects on selectivity, impulsivity and compulsivity. Behav Brain Res. 2003;146:105-119.
60. Dickstein SG, Bannon K, Castellanos FX, Milham MP. The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. J Child Psychol Psychiatry. 2006;47:1051-1062.
61. Carboni E, Silvagni A. Dopamine reuptake by norepinephrine neurons: exception or rule? Crit Rev Neurobiol. 2004;16:121-128.
62. Mork A, Witten LM, Arnt J. Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology (Berl). 2009;206:39-49.
63. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 1999;288:774-781.
64. Ichikawa J, Dai J, Meltzer HY. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT(1A) receptor agonism. Brain Res. 2005;1049:182-190.
65. Ohmura Y, Tsutsui-Kimura I, Kumamoto H, Minami M, Izumi T, Yamaguchi T, et al. Lithium, but not valproic acid or carbamazepine, suppresses impulsive-like action in rats. Psychopharmacology (Berl). 2012;219:421-432.
66. Greenslade RG, Mitchell SN. Selective action of (-)-2-oxa-4- aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell. Neuropharmacology. 2004;47:1-8.
67. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol. 2002;13:451-463.
68. Pattij T, Janssen MC, Schepers I, González-Cuevas G, de Vries TJ, Schoffelmeer AN. Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats. Psychopharmacology (Berl). 2007;193:85-96.
69. Shearman E, Fallon S, Sershen H, Lajtha A. Nicotine-induced monoamine neurotransmitter changes in the brain of young rats. Brain Res Bull. 2008;76:626-639.
70. Harrison AA, Everitt BJ, Robbins TW. Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology (Berl). 1997;133:329-342.
71. Fu Y, Matta SG, James TJ, Sharp BM. Nicotine-induced norepinephrine release in the rat amygdala and hippocampus is mediated through brainstem nicotinic cholinergic receptors. J Pharmacol Exp Ther. 1998;284:1188-1196.
72. Puumala T, Riekkinen P Sr, Sirvio J. Modulation of vigilance and behavioral activation by alpha-1 adrenoceptors in the rat. Pharmacol Biochem Behav. 1997;56:705-712.
73. Koskinen T, Haapalinna A, Sirvio J. Alpha-adrenoceptor-mediated modulation of 5-HT2 receptor agonist induced impulsive responding in a 5-choice serial reaction time task. Pharmacol Toxicol. 2003;92:214-225.
74. Potter AS, Newhouse PA. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/ hyperactivity disorder. Psychopharmacology (Berl). 2004;176:182-194.
75. Potter AS, Newhouse PA. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav. 2008;88:407-417.
76. Newhouse PA. From MCI to ADHD: targeting nAChRs for cognitive/ attention disorders. Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium in Lincolnshire, Illinois on October 15, 2009.
77. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996;123:55-63.
78. Levin ED, Conners CK, Silva D, Canu W, March J. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol. 2001;9:83-90.
79. Broersen LM, Uylings HB. Visual attention task performance in Wistar and Lister hooded rats: response inhibition deficits after medial prefrontal cortex lesions. Neuroscience. 1999;94:47-57.
80. Kates WR, Frederikse M, Mostofsky SH, Folley BS, Cooper K, Mazur-Hopkins P, et al. MRI parcellation of the frontal lobe in boys with attention deficit hyperactivity disorder or Tourette syndrome. Psychiatry Res. 2002;116:63-81.
81. Hill DE, Yeo RA, Campbell RA, Hart B, Vigil J, Brooks W. Magnetic resonance imaging correlates of attention-deficit/ hyperactivity disorder in children. Neuropsychology. 2003;17:496-506.
82. Seidman LJ, Valera EM, Makris N, Monuteaux MC, Boriel DL, Kelkar K, et al. Dorsolateral prefrontal and anterior cingulate cortex volumetric abnormalities in adults with attention-deficit/ hyperactivity disorder identified by magnetic resonance imaging. Biol Psychiatry. 2006;60:1071-1080.
83. Makris N, Biederman J, Valera EM, Bush G, Kaiser J, Kennedy DN, et al. Cortical thinning of the attention and executive function networks in adults with attention-deficit/hyperactivity disorder. Cereb Cortex. 2007;17:1364-1375.
84. Ellison-Wright I, Bullmore E. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophr Res. 2010;117:1-12.
85. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Metaanalysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 2009;66:811-822.
86. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett. 2000;285:107-110.
87. Larisch R, Sitte W, Antke C, Nikolaus S, Franz M, Tress W, et al. Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl Med Commun. 2006;27:267-270.
88. Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, et al. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry. 2007;62:1059-1061.
89. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV, et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage. 2007;34:1182-1190.
90. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302:1084-1091.
91. Hesse S, Ballaschke O, Barthel H, Sabri O. Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res. 2009;171:120-128.
92. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Laane K, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science. 2007;315:1267-1270.
93. Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Li R, Ansari MS, et al. Dopaminergic network differences in human impulsivity. Science. 2010;329:532.
94. van Gaalen MM, Brueggeman RJ, Bronius PF, Schoffelmeer AN, Vanderschuren LJ. Behavioral disinhibition requires dopamine receptor activation. Psychopharmacology (Berl). 2006;187:73-85.
95. Ross HD, Chan KK, Piraino AJ, John VA. Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. Pharm Res. 1991;8:385-388.
96. Gilman SL, Xun Z. Smoke: a global history of smoking. London: Reaktion Books; 2004.
97. Ghosheh O, Dwoskin LP, Li WK, Crooks PA. Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2?-(14)C]nicotine. Drug Metab Dispos. 1999;27:1448-1455.
98. Ohmura Y, Jutkiewicz EM, Zhang A, Domino EF. Dopamine D1/5 and D2/3 agonists differentially attenuate somatic signs of nicotine withdrawal in rats. Pharmacol Biochem Behav. 2011;99:552-556.
99. Hobara N, Yoshida N, Goda M, Yokomizo A, Kitamura Y, Sendou T, et al. Neurotrophic effect of hepatic growth factor (HGF) on reinnervation of perivascular calcitonin gene-related peptide (CGRP)-containing nerves following phenol-induced nerve injury in the rat mesenteric artery. J Pharmacol Sci. 2008;108:495-504.
100. Semenova S, Stolerman IP, Markou A. Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacol Biochem Behav. 2007;87:360-368.